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Abstract: Mature T-cell lymphomas are aggressive malignancies. Treatment outcome is 
poor with conventional chemotherapy. They are about twice as common in Asia as compared 
with other non-Asian countries. Histone proteins form the basic structure of chromatin, and 
their acetylation at lysine residues relaxes chromatin structure, facilitating gene transcription. 
Conversely, histone deacetylation, catalyzed by histone deacetylases, compacts chromatin 
and represses gene transcription. Histone deacetylase inhibitors are an important class of 
antineoplastic agents. Chidamide is a novel orally active benzamide-type histone deacetylase 
inhibitor that has shown in vitro activities against a wide array of neoplasms. In Phase I trials, 
chidamide showed preferential efficacy in mature T-cell lymphomas. In a pivotal Phase II trial 
of chidamide in 79 patients with relapsed or refractory mature T-cell lymphomas, an overall 
response rate of 28% (complete remission/complete remission unconfirmed: 14%) was achieved, 
with most responses occurring within the first 6 weeks of treatment. The median duration of 
response (DOR) was 9.9 (1.1–40.8) months. Of 22 responders, 19 patients (86%) had a DOR 
of $3 months and eight patients (36%) had a DOR of .12 months. Angioimmunoblastic T-cell 
lymphoma and anaplastic large cell lymphoma (anaplastic lymphoma kinase-negative) showed 
better response rates, with the most durable responses observed in angioimmunoblastic T-cell 
lymphoma patients. Safety profile was favorable, with very few cases of grade 3/4 toxicities 
observed. Chidamide is approved by the China Food and Drug Administration for the treatment 
of relapsed and refractory peripheral T-cell lymphomas.
Keywords: chidamide, peripheral T-cell lymphoma, benzamide, histone deacetylase inhibitors
Mature T-cell lymphomas
Mature T-cell lymphomas are a heterogeneous group of T-cell malignancies derived 
from postthymic mature T lymphocytes. There are geographical variations in their 
distribution. Mature T-cell lymphomas account for ∼5%–10% of lymphomas in 
Western countries.1 In Asian countries, however, they may account for up to 20% of all 
lymphomas.2 The classification of mature T-cell lymphomas relies on their predominant 
sites of involvement and clinical behavior. For nodal mature T-cell lymphomas, the 
most common subtypes include peripheral T-cell lymphoma, not otherwise specified, 
angioimmunoblastic T-cell lymphoma (AITL), and anaplastic large cell lymphoma 
(ALCL). For extranodal mature T-cell lymphomas, there is also a geographical varia-
tion in their incidences. In the West, the most common ones are cutaneous T-cell 
lymphomas, with mycosis fungoides occurring at the highest frequency.1 However, 
in Asia, extranodal NK/T-cell lymphoma, nasal type, is most frequent.2 Cutaneous 
T-cell lymphomas are very uncommon in Asian populations.
There is currently no standard chemotherapeutic regimen for nodal mature T-cell 
lymphomas. With the exception of anaplastic lymphoma kinase-positive ALCL and 
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primary cutaneous ALCL, the response to conventional 
anthracycline-containing regimens remains poor.1 In a study 
involving 340 patients with peripheral T-cell lymphoma, 
not otherwise specified, the reported 5-year overall survival 
(OS) and failure-free survival were poor at 32% and 20%, 
respectively. The addition of anthracycline did not seem to 
affect the outcome.3
Trials evaluating intensification of chemotherapy 
have resulted in variable success in prolonging event-free 
survival,4–6 but OS has remained unchanged. These results 
show that dose-intensified chemotherapy does not appear to 
be superior to conventional anthracycline-based regimens. 
Consequently, the use of high-dose chemotherapy and 
autologous hematopoietic stem cell transplantation has 
also been advocated as a consolidation strategy for patients 
who achieve a complete remission (CR).7,8 Improvement in 
progression-free survival (PFS) and OS is achievable, but 
the strategy is limited to patients who are in CR after initial 
chemotherapy. However, many patients are ineligible for 
hematopoietic stem cell transplantation, because of age or 
failure to achieve remission.
Given the poor results with cytotoxic chemotherapy, there 
is a pressing need for the development of novel treatment 
strategies for mature T-cell lymphomas.9
Epigenetics, histone deacetylase, 
and cancer
Carcinogenesis can be due to genetic mutations that change 
DNA sequences. The results are either increased expression 
of oncogenes or decreased expression of tumor suppressor 
genes. However, gene expression can also be affected by 
other pathogenetic mechanisms. Epigenetic modifications are 
defined as heritable changes in gene expression that are not 
due to alterations in DNA sequence.10 There are two major 
epigenetic processes in cancer,11 DNA hypermethylation and 
posttranslational histone modification.
Methylation of DNA occurs at sites where there are 
cytosines preceding guanines (CpGs). These CpGs are dis-
tributed nonrandomly and are particularly concentrated as 
islands in close proximity to gene promoters. Methylation of 
the cytosine residuals in these CpG islands in general results 
in suppression of gene expression. Hence, hypermethylation 
of CpG islands in the promoters of tumor suppressor genes 
constitutes an important pathogenetic mechanism in many 
cancers. Examples of tumor suppressor genes inactivated 
by promoter DNA hypermethylation include RB,12 P16,13 
and BRCA1.14
Histone proteins form the basic repeating units of chro-
matin and provide a spool for DNA to wrap around.15,16 
The amino terminal tails of histone proteins protrude out of 
the nucleosomes. The acetylation of histones is an epigenetic 
phenomenon that modulates gene transcription. Acetylation 
of the ε-amino group of lysine residues in the amino terminal 
tails of histone proteins, catalyzed by histone acetyltrans-
ferases, neutralizes their positive charges, resulting in relax-
ation of chromatin structure, thereby allowing better access 
of transcription factors to their target genes.15 Acetylated 
histones also provide binding sites for bromodomain proteins, 
which are transcriptional activators. On the other hand, the 
removal of an acetyl group from lysine residues, catalyzed by 
histone deacetylases (HDACs), results in chromatin conden-
sation and hence repression of gene transcription.15 HDACs 
play important roles in the control of gene transcription and 
affect multiple cellular processes.16
HDAC
Classical HDACs can be categorized into four classes, I, IIa, 
IIb, and IV; according to their homology with their corre-
sponding yeast proteins.16 They are zinc-dependent proteases 
with very high deacetylase activities for substrates.15 Class I 
HDACs are localized mainly to the nucleus and are found 
ubiquitously in different tissues and organs. Deletion of 
any of them is lethal in mice, showing that they are nonre-
dundant, with each controlling specific cellular processes.15 
Class II HDACs shuttle in and out of the nucleus and are more 
restricted in their tissue distribution. Another type of HDAC, 
often called class III HDACs, are NAD-dependent proteins. 
Referred also to as sirtuins, class III HDACs (sirtuins 1–7) 
are implicated in influencing a broad range of processes other 
than control of gene transcription, including apoptosis, aging, 
and inflammation.15
HDACs play important roles in oncogenesis. Class I 
HDACs inhibit apoptosis and promote cellular proliferation. 
Class II HDACs may enhance angiogenesis.15,16 Hence, inhi-
bition of HDAC is a valid strategy in cancer therapy.
HDAC inhibitors
Classical HDACs are zinc dependent. HDAC inhibitors 
(HDACis), therefore, typically contain a moiety that occupies 
the catalytic core of the zinc-binding site, thereby interfering 
with zinc binding. Hence, HDACi targeting class I and II 
HDACs has a general structure consisting of a zinc-chelating 
moiety, a linker, and an external surface recognition motif. 
Depending on the zinc-chelating moieties, HDACi can be 
divided into two broad categories, hydroxamic acid deriva-
tives and nonhydroxamic acid derivatives. Three types of 
nonhydroxamic acid derivatives can be distinguished: thiol 
and thiol derivatives, benzamides, and ketones (Table 1).16
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Chidamide
Chidamide is an orally active novel benzamide-type 
HDACi, designed with molecular docking analysis employ-
ing HDAC-like protein and quantitative structure–activity 
relationship studies.17 It has a high affinity for class I HDAC 
(IC
50
 for HDAC1: 0.095 µM; HDAC2: 0.16 µM; and 
HDAC3: 0.067 µM) and class IIb HDAC (IC
50
 for HDAC10: 
0.075 µM).17 It has minimal inhibitory activity against 
other class I, IIa, and IV HDACs. Chidamide treatment 
leads to increased acetylation of histone H3 at Lys9/Lys18 
and H4 at Lys8, resulting ultimately in activation of gene 
transcription.17
Preclinical studies of chidamide
Chidamide has been tested extensively for its tumor inhibi-
tory activity. In colonic cancer cell lines, chidamide inhibited 
the PI3K/AKT and RAS/MAPK signaling pathways, leading 
to cell cycle arrest and hence suppression of proliferation.18 
In leukemia lines, chidamide induced caspase-dependent 
apoptosis through generation of reactive oxygen species, 
resulting in mitochondrial dysfunction and cytochrome 
c release.19 In hepatocellular carcinoma cells, chidamide 
upregulated the cyclin-dependent kinase inhibitor P21, 
leading to cell cycle arrest.20 In pancreatic cancer cell lines 
and in vivo tumors, chidamide treatment upregulated the 
proapoptotic BAX/BCL2 expression ratio and suppressed 
cellular proliferation by promoting mitochondrial pathway-
dependent cell apoptosis.21
Chidamide may also synergize with chemotherapeutic 
agents. In pancreatic cancer cell lines, chidamide enhanced 
gemcitabine-induced cell growth arrest and apoptosis in a 
synergistic manner, which was due to downregulation of the anti-
apoptotic protein MCL-1 and loss of mitochondrial membrane 
potential. Chidamide also increased gemcitabine-induced DNA 
double-strand breaks and S phase arrest and suppressed CHK1 
expression, thereby abrogating the G2/M cell cycle checkpoint.22 
In non-small-cell lung cancer cell lines, chidamide synergized 
with carboplatin in suppressing cellular proliferation.23 There 
was increase in carboplatin-induced apoptosis, as measured 
by mitochondrial membrane potential and cleaved PARP1 
levels. Combination with other platinum drugs including 
cisplatin and oxaliplatin showed similar effects.23 In a murine 
xenograft model of colonic cancer, chidamide combined with 
5-fluorouracil increased P53, phosphorylated-P53, and P21 
levels, but suppressed cyclin-dependent kinase 4 expression 
in tumor cells. The combination also blocked signaling via the 
AKT, mTOR, RAF, and ERK1/2 pathways.24
Chidamide may also modulate antitumor immune mecha-
nisms. The ex vivo cytotoxic effects of peripheral blood 
mononuclear cells, particularly natural killer cells, on target 
leukemia cell lines were increased by chidamide.17 Treatment 
of myeloid leukemia cells (primary samples and cell lines) 
with chidamide led to increased expression of the potentially 
immunogenic antigen preferentially expressed antigen of 
melanoma, which was further enhanced by the demethylating 
agent decitabine.25 Accordingly, pretreatment of leukemia 
cell line cells with chidamide and/or decitabine increased 
their sensitivity to purified cytotoxic T-cells that recognized 
preferentially expressed antigen of melanoma.25 These results 
suggest that chidamide treatment may also target neoplastic 
cells indirectly via immune mechanisms.
Phase I study of chidamide in 
patients with advanced solid tumors 
and lymphomas
The Phase I study was designed to recruit patients with 
advanced solid tumors or lymphomas that were refractory to 
standard treatment.26 Chidamide used as a single agent was 
administered orally in sequential cohorts of 5 mg, 10 mg, 
17.5 mg, 25 mg, 32.5 mg, or 50 mg, either twice (biw) or three 
times (tiw) per week for 4 consecutive weeks every 6 weeks.
Thirty-one patients were enrolled. At 50 mg biw, two of 
four patients developed grade 3 hematologic toxicities. At 
50 mg tiw, two patients experienced dose-limiting adverse 
events (grade 3 diarrhea, grade 3 nausea, and vomiting). 
At 32.5 mg tiw, four of seven patients experienced grade 3 
hematologic adverse events. Therefore, the maximum toler-
ated dose for the biw dosing schedule was set at 50 mg and 
for the tiw dosing schedule at 32.5 mg.
Pharmacokinetic studies showed that plasma chidamide 
concentrations peaked in the majority of patients within 
0.5–2 hours of drug administration and returned to baseline 
levels in 48 hours. Elimination half-life ranged from 16 hours 
to 18 hours.
Adverse events are shown in Table 2. In general, chi-
damide appeared to be very well tolerated, and significant 
Table 1 Types of histone deacetylase inhibitors and their current 
approval status in the treatment of mature T-cell lymphomas
Type Examples Regulatory approval 
for T-cell lymphoma
Hydroxamic acids vorinostat Yes (US FDA)
Belinostat Yes (US FDA)
Panobinostat No
Short-chain aliphatic acids Phenylbutyrate No
valproic acid No
Cyclic tetrapeptides Romidepsin Yes (US FDA)
Benzamides Chidamide Yes (China FDA)
Abbreviation: FDA, Food and Drug Administration.
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toxicity (. grade 3) was only observed in the 32.5 mg tiw 
and the 50 mg tiw cohorts.
Twenty-five patients were evaluable. The best response 
was partial remission in five patients and stable disease in 
eleven patients. Four of the five patients with partial remis-
sion had mature T-cell lymphoma (Table 3). These obser-
vations provided the basis for testing chidamide in mature 
T-cell lymphoma.
Pivotal Phase II study of chidamide 
in relapsed or refractory peripheral 
T-cell lymphoma
The pivotal Phase II study was an open-label, single-arm, 
multicenter investigation of chidamide monotherapy in 
peripheral T-cell lymphomas that had relapsed from or 
were refractory to one or more systemic therapies.27 Final 
eligibility required central pathology review for confirmation 
of diagnosis. Patients received chidamide at 30 mg biw 
until disease progression, unacceptable toxicity, or patient/
investigator withdrawal. The primary end point was over-
all response rate. Secondary end points included time to 
response, duration of response (DOR), PFS, proportion of 
patients with DOR $12 weeks, OS, and profile of adverse 
events. Efficacy was assessed every 6 weeks, with results 
verified by an independent review committee.
Seventy-nine patients were evaluable. The overall 
response rate was 28% (CR/CR unconfirmed: 14%; partial 
remission: 14%). Most responses occurred within the first 
6 weeks of treatment, although some responses occurred at as late 
as 18 weeks. The median DOR was 9.9 (1.1–40.8) months. Of 
the 22 responders, 19 patients (86%) had a DOR of $3 months, 
and eight patients (36%) had a DOR of .12 months. No 
specific factors impacted on outcome, although AITL and 
anaplastic lymphoma kinase-negative ALCL appeared to 
Table 2 Adverse events of chidamide in .5% of patients in clinical trials
Adverse events Total 
number 
Percentage Grade 3 
number
Percentage Grade 4 
number 
Percentage 
Phase i (N=31)a 
Fatigue 11 35 0 0 0 0
Thrombocytopenia 8 26 2 6 0 0
Anorexia 8 26 2 6 0 0
Leukopenia 7 23 3 10 0 0
Anemia 6 19 0 0 0 0
Nausea 5 16 0 0 0 0
Diarrhea 5 16 1 3 0 0
Dizziness 4 13 0 0 0 0
vomiting 2 6 1 3 0 0
Flatulence 2 6 0 0 0 0
Hemoptysis 2 6 0 0 0 0
insomnia 2 6 0 0 0 0
Headache 2 6 0 0 0 0
Phase ii (N=83)b
Thrombocytopenia 42 51 13 16 5 6
Leukopenia 33 40 10 12 1 1
Neutropenia 18 22 7 8 2 2
Prolonged QTc interval 11 13 1 13 0 0
Fatigue 8 10 0 0 0 0
Anemia 7 8 3 4 1 1
Decreased appetite 7 8 2 2 0 0
Fever 7 8 0 0 0 0
Nausea 7 8 0 0 0 0
Diarrhea 7 8 0 0 0 0
Pericardial effusion 6 7 0 0 0 0
increased ALT 6 7 1 1 0 0
increase GGT 5 6 1 1 0 0
increased CPK 5 6 0 0 0 0
Lung infection 5 6 1 1 0 0
Notes: ain patients with solid tumors and different lymphomas. Data from a previous study.26 bin patients with T-cell lymphomas. Reproduced and adapted, with permission, 
from Y Shi et al. Results From A Multicenter, Open-Label, Pivotal Phase ii Study Of Chidamide in Relapsed Or Refractory Peripheral T-Cell Lymphoma. Annals of Oncology. 
2015;26 (8):1766–1771.27 Published by Oxford University Press on behalf of the european Society for Medical Oncology online at: http://annonc.oxfordjournals.org/
content/26/8/1766.abstract. Published under a Standard License only. For permissions please email: journals.permissions@oup.com.
Abbreviations: N, number of patients; ALT, alanine aminotransferase; GGT, gamma-glutamyl transferase; CPK, creatine phosphokinase.
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have more favorable response rates (Table 3). In fact, the 
most durable responses were seen in three patients with AITL. 
The median PFS was 2.1 (0.3–44.9) months, and the median 
OS was 21.4 (0.3–50.1) months.
Adverse events occurred in 82% of patients (Table 2). 
Those that occurred in $10% patients were thrombocytopenia 
(51%), leukopenia (40%), neutropenia (22%), and fatigue 
(10%). Adverse events of $ grade 3 were thrombocytopenia 
(22%), leukopenia (13%), and neutropenia (11%). Hematologic 
toxicities occurred mostly in the first 6 weeks of treatment. 
These adverse events led to drug discontinuation in 14 patients 
(17%) and dose reduction in six patients (7%). Prolongation of 
QTc interval was observed in eleven patients (13%).
These results indicate that chidamide has significant 
activity against mature T-cell lymphomas. Its efficacy is 
similar to those observed in two other HDACis, romidepsin28 
and belinostat.29 A recent study of romidepsin treatment of 
Epstein–Barr virus (EBV)-positive NK/T-cell lymphoma 
resulted in fatal EBV reactivation in some cases, suggest-
ing that histone deacetylation might contribute to suppres-
sion of EBV proliferation in infected tumor cells.30 Hence, 
care should be exercised in the use of chidamide and other 
HDACi in EBV-positive lymphomas. Among the currently 
available HDACi, chidamide has the advantage of being an 
oral medication. It was approved by the China Food and Drug 
Administration for the treatment of relapsed and refractory 
peripheral T-cell lymphoma in December 2014.
Ongoing studies of chidamide
Chidamide is now undergoing clinical trials in Asia and North 
America, predominantly in lymphoma patients. Since the 
number of patients with cutaneous T-cell lymphoma treated 
with chidamide was small, the testing of this drug in such 
patients will be of interest. Finally, it remains to be defined if 
chidamide in combination with chemotherapy may be more 
effective than its use as single agent.
Conclusion
Chidamide is a novel HDACi that has demonstrated signifi-
cant therapeutic efficacy in peripheral T-cell lymphomas, 
which is achieved with a very favorable toxicity profile. 
Future studies should define if combination of chidamide 
with other targeted drugs or chemotherapy may have 
increased efficacy in peripheral T-cell lymphomas, the treat-
ment of which remains a challenge.
Disclosure
The authors report no conflicts of interest in this work.
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